Adaptimmune Property Plant Equipment vs Current Deferred Revenue Analysis

ADAP Stock

USD 1.06 0.05 4.95%

Adaptimmune Therapeutics financial indicator trend analysis is way more than just evaluating Adaptimmune Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Adaptimmune Therapeutics is a good investment. Please check the relationship between Adaptimmune Therapeutics Property Plant Equipment and its Current Deferred Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptimmune Therapeutics Plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Property Plant Equipment vs Current Deferred Revenue

Property Plant Equipment vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Adaptimmune Therapeutics Property Plant Equipment account and Current Deferred Revenue. At this time, the significance of the direction appears to have almost no relationship.

The correlation between Adaptimmune Therapeutics' Property Plant Equipment and Current Deferred Revenue is 0.16. Overlapping area represents the amount of variation of Property Plant Equipment that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Adaptimmune Therapeutics Plc, assuming nothing else is changed. The correlation between historical values of Adaptimmune Therapeutics' Property Plant Equipment and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Property Plant Equipment of Adaptimmune Therapeutics Plc are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Property Plant Equipment i.e., Adaptimmune Therapeutics' Property Plant Equipment and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

0.16

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Property Plant Equipment

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most indicators from Adaptimmune Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Adaptimmune Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptimmune Therapeutics Plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

As of 06/06/2024, Selling General Administrative is likely to drop to about 37.2 M. In addition to that, Tax Provision is likely to drop to about 832.7 K

	2021	2022	2023	2024 (projected)
Net Interest Income	1.1M	1.5M	6.0M	6.3M
Interest Income	1.1M	1.5M	6.0M	6.3M

Net Interest Income Interest Income

Adaptimmune Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Short Long Term Debt Total	Common Stock Shares Outstanding	Short Term Debt	Property Plant Equipment	Net Tangible Assets
Total Assets		0.31	0.61	0.77	0.63	-0.38	-0.6	0.6	0.63	0.66	0.39	0.96	0.15	0.83	0.59	0.7	0.79	0.63	0.47	0.99	0.77	0.2	-0.79	0.04	0.51	0.83
Other Current Liab	0.31		0.74	-0.04	0.5	0.19	-0.51	0.21	-0.08	0.51	-0.04	0.18	0.18	0.4	0.42	0.49	0.52	0.52	0.4	0.24	0.39	0.06	0.01	-0.08	0.41	0.0
Total Current Liabilities	0.61	0.74		0.17	0.7	-0.17	-0.65	0.66	0.38	0.73	0.2	0.47	0.36	0.68	0.61	0.58	0.7	0.74	0.61	0.54	0.66	0.2	-0.42	0.05	0.67	0.24
Total Stockholder Equity	0.77	-0.04	0.17		0.12	-0.25	-0.01	0.34	0.53	0.26	0.62	0.85	-0.31	0.38	-0.05	0.35	0.34	-0.01	-0.07	0.81	0.29	0.49	-0.78	0.22	-0.02	0.99
Property Plant And Equipment Net	0.63	0.5	0.7	0.12		-0.02	-0.96	0.67	0.18	0.93	0.18	0.42	0.58	0.94	0.81	0.79	0.89	0.86	0.92	0.52	0.94	-0.22	-0.47	-0.38	0.94	0.23
Net Debt	-0.38	0.19	-0.17	-0.25	-0.02		0.11	-0.11	-0.87	0.08	0.07	-0.46	-0.29	-0.22	-0.31	0.13	-0.06	-0.3	-0.13	-0.45	-0.26	-0.24	0.46	-0.71	-0.09	-0.27
Retained Earnings	-0.6	-0.51	-0.65	-0.01	-0.96	0.11		-0.54	-0.19	-0.84	0.04	-0.41	-0.67	-0.91	-0.92	-0.71	-0.89	-0.93	-0.93	-0.5	-0.93	0.36	0.33	0.38	-0.91	-0.14
Accounts Payable	0.6	0.21	0.66	0.34	0.67	-0.11	-0.54		0.31	0.75	0.46	0.46	0.21	0.67	0.44	0.63	0.66	0.52	0.55	0.52	0.63	0.11	-0.58	-0.05	0.57	0.41
Cash	0.63	-0.08	0.38	0.53	0.18	-0.87	-0.19	0.31		0.16	0.27	0.68	0.26	0.42	0.3	0.07	0.24	0.34	0.22	0.68	0.43	0.52	-0.75	0.65	0.25	0.56
Non Current Assets Total	0.66	0.51	0.73	0.26	0.93	0.08	-0.84	0.75	0.16		0.34	0.44	0.32	0.86	0.66	0.85	0.94	0.71	0.75	0.54	0.83	-0.14	-0.51	-0.38	0.81	0.34
Other Assets	0.39	-0.04	0.2	0.62	0.18	0.07	0.04	0.46	0.27	0.34		0.37	-0.21	0.28	-0.24	0.27	0.18	-0.15	0.05	0.37	0.2	0.54	-0.68	0.1	0.14	0.6
Cash And Short Term Investments	0.96	0.18	0.47	0.85	0.42	-0.46	-0.41	0.46	0.68	0.44	0.37		0.05	0.68	0.44	0.54	0.6	0.47	0.29	0.99	0.62	0.31	-0.78	0.18	0.31	0.89
Net Receivables	0.15	0.18	0.36	-0.31	0.58	-0.29	-0.67	0.21	0.26	0.32	-0.21	0.05		0.56	0.62	-0.01	0.35	0.64	0.85	0.11	0.67	-0.18	-0.12	-0.04	0.76	-0.16
Common Stock Total Equity	0.83	0.4	0.68	0.38	0.94	-0.22	-0.91	0.67	0.42	0.86	0.28	0.68	0.56		0.8	0.75	0.91	0.84	0.87	0.75	0.99	-0.07	-0.66	-0.22	0.88	0.5
Non Current Liabilities Total	0.59	0.42	0.61	-0.05	0.81	-0.31	-0.92	0.44	0.3	0.66	-0.24	0.44	0.62	0.8		0.64	0.79	0.98	0.8	0.52	0.82	-0.39	-0.23	-0.27	0.78	0.05
Other Current Assets	0.7	0.49	0.58	0.35	0.79	0.13	-0.71	0.63	0.07	0.85	0.27	0.54	-0.01	0.75	0.64		0.85	0.66	0.5	0.61	0.66	-0.17	-0.45	-0.44	0.57	0.38
Other Stockholder Equity	0.79	0.52	0.7	0.34	0.89	-0.06	-0.89	0.66	0.24	0.94	0.18	0.6	0.35	0.91	0.79	0.85		0.81	0.74	0.69	0.87	-0.21	-0.48	-0.35	0.76	0.43
Total Liab	0.63	0.52	0.74	-0.01	0.86	-0.3	-0.93	0.52	0.34	0.71	-0.15	0.47	0.64	0.84	0.98	0.66	0.81		0.84	0.56	0.86	-0.27	-0.3	-0.21	0.83	0.09
Property Plant And Equipment Gross	0.47	0.4	0.61	-0.07	0.92	-0.13	-0.93	0.55	0.22	0.75	0.05	0.29	0.85	0.87	0.8	0.5	0.74	0.84		0.38	0.92	-0.23	-0.36	-0.28	0.96	0.08
Total Current Assets	0.99	0.24	0.54	0.81	0.52	-0.45	-0.5	0.52	0.68	0.54	0.37	0.99	0.11	0.75	0.52	0.61	0.69	0.56	0.38		0.69	0.26	-0.78	0.12	0.4	0.86
Common Stock	0.77	0.39	0.66	0.29	0.94	-0.26	-0.93	0.63	0.43	0.83	0.2	0.62	0.67	0.99	0.82	0.66	0.87	0.86	0.92	0.69		-0.1	-0.61	-0.2	0.91	0.42
Short Long Term Debt Total	0.2	0.06	0.2	0.49	-0.22	-0.24	0.36	0.11	0.52	-0.14	0.54	0.31	-0.18	-0.07	-0.39	-0.17	-0.21	-0.27	-0.23	0.26	-0.1		-0.51	0.71	-0.12	0.46
Common Stock Shares Outstanding	-0.79	0.01	-0.42	-0.78	-0.47	0.46	0.33	-0.58	-0.75	-0.51	-0.68	-0.78	-0.12	-0.66	-0.23	-0.45	-0.48	-0.3	-0.36	-0.78	-0.61	-0.51		-0.28	-0.43	-0.81
Short Term Debt	0.04	-0.08	0.05	0.22	-0.38	-0.71	0.38	-0.05	0.65	-0.38	0.1	0.18	-0.04	-0.22	-0.27	-0.44	-0.35	-0.21	-0.28	0.12	-0.2	0.71	-0.28		-0.27	0.19
Property Plant Equipment	0.51	0.41	0.67	-0.02	0.94	-0.09	-0.91	0.57	0.25	0.81	0.14	0.31	0.76	0.88	0.78	0.57	0.76	0.83	0.96	0.4	0.91	-0.12	-0.43	-0.27		0.11
Net Tangible Assets	0.83	0.0	0.24	0.99	0.23	-0.27	-0.14	0.41	0.56	0.34	0.6	0.89	-0.16	0.5	0.05	0.38	0.43	0.09	0.08	0.86	0.42	0.46	-0.81	0.19	0.11

Click cells to compare fundamentals

Adaptimmune Therapeutics Account Relationship Matchups

Adaptimmune Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	181.5M	451.1M	469.5M	328.9M	282.6M	268.1M
Other Current Liab	23.4M	27.1M	29.9M	33.5M	30.3M	21.7M
Total Current Liabilities	34.3M	39.1M	62.5M	64.5M	72.8M	44.6M
Total Stockholder Equity	123.6M	341.2M	206.0M	81.9M	39.5M	37.5M
Property Plant And Equipment Net	51.9M	46.7M	51.4M	71.5M	71.7M	75.3M
Net Debt	(25.0M)	(33.2M)	(124.5M)	(85.0M)	(118.8M)	(112.8M)
Retained Earnings	(455.7M)	(585.8M)	(743.8M)	(909.3M)	(1.0B)	(972.0M)
Accounts Payable	6.4M	6.4M	8.1M	4.8M	8.1M	5.5M
Cash	50.4M	56.9M	149.9M	108.0M	144.0M	112.8M
Non Current Assets Total	61.1M	53.0M	54.1M	73.5M	75.1M	39.1M
Other Assets	7.0M	4.6M	1.7M	1.6M	1.8M	1.7M
Cash And Short Term Investments	89.5M	368.2M	369.6M	204.6M	146.9M	202.8M
Net Receivables	(1.5M)	139K	752K	7.4M	46.9M	49.3M
Common Stock Total Equity	939K	943K	1.3M	1.3M	1.5M	1.6M
Liabilities And Stockholders Equity	181.5M	451.1M	469.5M	328.9M	282.6M	268.1M
Non Current Liabilities Total	23.6M	70.8M	201.0M	182.5M	170.3M	178.8M
Other Current Assets	30.9M	29.8M	45.1M	43.3M	13.7M	19.3M
Other Stockholder Equity	585.6M	935.7M	959.6M	990.7M	1.1B	535.2M
Total Liab	57.9M	109.9M	263.6M	247.0M	243.1M	255.3M
Property Plant And Equipment Gross	51.9M	46.7M	51.4M	71.5M	130.9M	137.5M
Total Current Assets	120.5M	398.2M	415.5M	255.4M	207.6M	229.0M
Accumulated Other Comprehensive Income	(7.3M)	(10.0M)	(11.1M)	(875K)	(3.7M)	(3.6M)
Common Stock	943K	1.3M	1.3M	1.4M	1.9M	2.0M
Short Long Term Debt Total	25.5M	23.7M	25.5M	23.1M	25.2M	38.5M
Common Stock Shares Outstanding	105.0M	142.5M	155.8M	161.2M	201.1M	129.5M
Property Plant Equipment	31.1M	27.8M	30.5M	71.5M	82.3M	86.4M
Net Tangible Assets	121.4M	339.5M	205.0M	81.4M	93.7M	89.0M
Non Currrent Assets Other	7.0M	4.6M	1.7M	1.6M	3.0M	3.6M
Short Term Investments	39.1M	311.3M	219.6M	96.6M	2.9M	2.8M
Other Liab	598K	49.9M	177.9M	162.2M	186.5M	195.8M
Inventory	1.5M	2.1M	746K	1.3M	1.3M	1.4M
Intangible Assets	2.2M	1.7M	1M	442K	330K	313.5K
Capital Surpluse	574.2M	585.6M	935.7M	959.6M	1.1B	657.5M
Retained Earnings Total Equity	(318.5M)	(455.7M)	(585.8M)	(743.8M)	(669.5M)	(636.0M)
Non Current Liabilities Other	23.6M	70.8M	201.0M	1.3M	1.4M	1.3M
Net Invested Capital	123.6M	341.2M	206.0M	81.9M	39.5M	37.5M
Net Working Capital	86.1M	359.1M	352.9M	190.9M	134.8M	233.6M
Capital Stock	943K	1.3M	1.3M	1.4M	1.9M	1.4M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Additional Tools for Adaptimmune Stock Analysis

When running Adaptimmune Therapeutics' price analysis, check to measure Adaptimmune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptimmune Therapeutics is operating at the current time. Most of Adaptimmune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Adaptimmune Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptimmune Therapeutics' price. Additionally, you may evaluate how the addition of Adaptimmune Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Adaptimmune Property Plant Equipment vs Current Deferred Revenue Analysis

Property Plant Equipment vs Current Deferred Revenue

Property Plant Equipment vs Current Deferred Revenue Correlation Analysis

Correlation Coefficient

Property Plant Equipment

Current Deferred Revenue

Adaptimmune Therapeutics fundamental ratios Correlations

Adaptimmune Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Adaptimmune Therapeutics fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Additional Tools for Adaptimmune Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 0.99	Total Assets
Net Tangible Assets	+ 0.99	Total Stockholder Equity
Total Current Assets	+ 0.99	Cash And Short Term Investments
Common Stock	+ 0.99	Common Stock Total Equity
Total Liab	+ 0.98	Non Current Liabilities Total
Cash And Short Term Investments	+ 0.96	Total Assets

Retained Earnings	- 0.96	Property Plant And Equipment Net
Common Stock	- 0.93	Retained Earnings
Property Plant And Equipment Gross	- 0.93	Retained Earnings
Total Liab	- 0.93	Retained Earnings
Non Current Liabilities Total	- 0.92	Retained Earnings
Property Plant Equipment	- 0.91	Retained Earnings